The Medical Advisor

Ivermectin and Fenbendazole in Cancer Care: A Functional Medicine Breakthrough As cancer diagnoses rise globally, the urgency for innovative, effective, and supportive therapies grows stronger. A peer-reviewed study has highlighted a groundbreaking protocol combining ivermectin, fenbendazole, and natural compounds such as Vitamin E, curcumin, and CBD. These elements, when used together, demonstrate significant potential in supporting cancer care.  The Study: A Synergistic Approach to Cancer Care The research reveals the combined effects of ivermectin, fenbendazole, and complementary compounds in addressing cancer at multiple levels. While traditionally known as antiparasitic drugs, ivermectin and fenbendazole, when used together, showed potential to modulate cancer pathways and support the body’s natural healing mechanisms. Key Findings from the Study 1. Immune System Modulation:  The protocol enhanced the immune system’s ability t...

The cancer drug market has experienced profound changes in recent years, marked by increased competition, shifting market shares, and the emergence of new players. While Merck, Roche and Bristol-Myers Squibb (BMS, with Celgene), and Merck remain influential, the landscape in 2025 will be far more dynamic and fragmented than before. This increased competition is fueled by the success of blockbuster drugs like Keytruda (Merck), Tagrisso (AstraZeneca), and Ibrance (Pfizer), as well as the rapid adoption of immunotherapies and targeted treatments ( Verified Market Reports ). And it won’t just be the heavy hitters clawing for a piece of the pie. That number is set to nearly double by 2024—swelling to 39.7%—thanks to big recent approvals for companies including Gilead Sciences, Eli Lilly, Tesaro, Clovis and more. This democratization of the market reflects both the rising number of new cancer cases globally and the surge in research and development, particularly in targeted therapies and per...